“…In general, the treatment of MPNs using disease modifiers is further complicated, as the specific treatment depends on the individual mutation [ 16 ]. Diagnosis of MPNs is aided by the detection of the various associated mutations by polymerase chain reaction, sequencing, or other DNA-based methods [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ], but the detection of disease-associated mutations may be facilitated or aided by mutation-specific immunohistochemistry (IHC) [ 31 , 32 , 33 ], methods which supplement each other. Moreover, antibodies such as these are invaluable reagents for studying the properties of CRT in relation to MPN.…”